MARKETING ANALYSIS OF THE RANGE OF HYPOLYPIDEMIC PRODUCTS ON THE PHARMACEUTICAL MARKET OF UKRAINE

Abstract

Formulation of the problem. Cardiovascular diseases are the main cause of mortality and disability in many countries of the world, and, according to forecasts, their prevalence will increase in the near future. Data from comparative statistical studies by WHO indicate that Ukraine ranks first in Europe and second in the world in the prevalence of cardiovascular diseases among the population. The purpose of the work is to analyze the domestic pharmaceutical market of hypolipidemic drugs in terms of pharmacotherapeutic groups, manufacturing companies, dosage forms, etc. Materials and methods of the study. The objects of the study are data from the State Register of Medicinal Products of Ukraine (as of 01.01.2025) on medicinal products of the second level subgroup of the ATC classification C10 «Lipid modifying agents», the ATC classification system, the State Formulary of Medicinal Products. Research results and their discussion. As a result of marketing research of the range of hypolipidemic drugs, it was found that as of January 1, 2025, 348 trade names were registered on the pharmaceutical market of Ukraine, taking into account all dosage forms and dosages. Market analysis showed the dominance of foreign manufacturers, namely Slovenia, India, Poland and others, over domestic manufacturers in the niche of production of mono– and combined hypolipidemic drugs. Ukrainian manufacturers are mostly focused on the production of C10AA group drugs – HMG-CoA reductase inhibitors (ten manufacturing companies), and only five out of ten companies produce combined drugs. Analysis of the assortment of subgroup C10 «Hypolipidemic agents» revealed that single-component preparations dominate the structure of the presented hypolipidemic agents, making up the largest share of the assortment. Among single-component hypolipidemic drugs, the most common is the subgroup C10AA «HMG-CoA reductase inhibitors». The distribution of the studied hypolipidemic drugs by type of dosage form shows that the main share of dosage forms is tablets and capsules. In the subgroup of combined drugs C10B, drugs containing rosuvastatin prevail. Conclusions. The structure of the assortment was studied and its analysis was carried out by subgroups of the ATC classification, by dosage forms, manufacturing countries and combinations of substances. It has been established that, despite the current availability of the domestic pharmaceutical market with hypolipidemic agents, in particular statins, the production activities of Ukrainian enterprises in this area are highly specialized. This leads to the dependence of the range of hypolipidemic drugs on foreign suppliers.